Top Healthcare Stocks Owned By Fidelity in Latest 13F Filing

Wall St. Watchdog reveals information regarding Fidelity’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 328 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $46.362 billion.

  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011 reported holding 53,520,999 shares with a market value of $2,760,613,226. This comprised 0.52% of the total portfolio. On 09/30/2011 reported holding 65,932,708 shares with a market value of $3,040,816,423. This comprised 0.7% of the total portfolio. The net change in shares for this position over the two quarters is 12,411,709. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011 reported holding 139,521,806 shares with a market value of $2,874,149,257. This comprised 0.54% of the total portfolio. On 09/30/2011 reported holding 124,685,193 shares with a market value of $2,204,434,250. This comprised 0.51% of the total portfolio. The net change in shares for this position over the two quarters is -14,836,613. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011 reported holding 39,860,064 shares with a market value of $2,325,834,674. This comprised 0.44% of the total portfolio. On 09/30/2011 reported holding 37,331,194 shares with a market value of $2,051,722,388. This comprised 0.47% of the total portfolio. The net change in shares for this position over the two quarters is -2,528,870. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Biogen Idec Inc. (NASDAQ:BIIB): On 06/30/2011 reported holding 16,415,973 shares with a market value of $1,755,195,803. This comprised 0.33% of the total portfolio. On 09/30/2011 reported holding 17,631,870 shares with a market value of $1,642,408,717. This comprised 0.38% of the total portfolio. The net change in shares for this position over the two quarters is 1,215,897. About Company: Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company’s products addresses diseases such as multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease, and psoriasis.
  • Alexion Pharmaceuticals Inc. (NASDAQ:ALXN): On 06/30/2011 reported holding 17,745,636 shares with a market value of $834,577,239. This comprised 0.16% of the total portfolio. On 09/30/2011 reported holding 23,227,973 shares with a market value of $1,487,983,894. This comprised 0.34% of the total portfolio. The net change in shares for this position over the two quarters is 5,482,337. About Company: Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The Company develops C5 complement inhibitors and Apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011 reported holding 49,021,768 shares with a market value of $1,729,978,238. This comprised 0.33% of the total portfolio. On 09/30/2011 reported holding 43,926,996 shares with a market value of $1,436,412,803. This comprised 0.33% of the total portfolio. The net change in shares for this position over the two quarters is -5,094,772. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Gilead Sciences Inc. (NASDAQ:GILD): On 06/30/2011 reported holding 40,483,331 shares with a market value of $1,676,414,731. This comprised 0.32% of the total portfolio. On 09/30/2011 reported holding 36,325,954 shares with a market value of $1,409,446,987. This comprised 0.32% of the total portfolio. The net change in shares for this position over the two quarters is -4,157,377. About Company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011 reported holding 25,459,312 shares with a market value of $1,693,553,349. This comprised 0.32% of the total portfolio. On 09/30/2011 reported holding 21,422,992 shares with a market value of $1,364,430,331. This comprised 0.31% of the total portfolio. The net change in shares for this position over the two quarters is -4,036,320. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Valeant Pharmaceuticals International (NYSE:VRX): On 06/30/2011 reported holding 43,701,801 shares with a market value of $2,270,745,540. This comprised 0.43% of the total portfolio. On 09/30/2011 reported holding 36,710,997 shares with a market value of $1,362,712,169. This comprised 0.31% of the total portfolio. The net change in shares for this position over the two quarters is -6,990,804. About Company: Valeant Pharmaceuticals International, Inc. develops and distributes drugs. The Company develops drugs for unmet medical needs in central nervous system disorders; and distributes generic and branded generic drugs in Latin America and Eastern Europe.
  • Covidien Plc (NYSE:COV): On 06/30/2011 reported holding 32,361,750 shares with a market value of $1,722,615,938. This comprised 0.33% of the total portfolio. On 09/30/2011 reported holding 28,941,222 shares with a market value of $1,276,307,846. This comprised 0.29% of the total portfolio. The net change in shares for this position over the two quarters is -3,420,528. About Company: Covidien PLC is a global healthcare products company. The Company develops, manufactures and distributes a diverse range of medical devices and supplies, diagnostics imaging agents, pharmaceuticals and other healthcare products for use in clinical and home settings.

(Note: Data regarding Fidelity’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet